Impact of Reimbursement for Biomarker Testing on Clinical Practice

Geoff Oxnard, MD
Thoracic Oncologist, Dana-Farber Cancer Institute,
Associate Professor of Medicine, Harvard Medical School,
Boston, MA
Lauren Ritterhouse, MD, PhD
Molecular Pathologist and Co-Director
Molecular Diagnostics and Clinical Genomics Laboratories, University of Chicago
Chicago, IL
Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”
Related Articles
An Interview with Gregory C. Simon, JD, About the Biden Cancer Initiative’s Strategies to Improve Cancer Care
Kristin Siyahian
|
March 2019 Vol 10, No 3
Use of Next-Generation Sequencing in Oncology
Lauren Ritterhouse, MD, PhD
|
Faculty Perspectives: Next-Generation Sequencing Testing in Oncology | Part 4 of a 4-Part Series
The advent of next-generation sequencing (NGS) technologies has revolutionized the way we approach and utilize molecular diagnostic testing in oncology.
Overcoming Challenges to Molecular Biomarker Testing
Geoff Oxnard, MD, Lauren Ritterhouse, MD, PhD
|
Video Library
Drs. Geoffrey Oxnard and Lauren Ritterhouse discuss the challenges in biomarker testing—tissue stewardship and complexity of biomarker tests and results—and ways to overcome these challenges—improved communication among all members of the cancer care team and simplification of biomarker test results to focus on actionable biomarkers.
Last modified: January 16, 2019

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
     
    Continue

  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code
    Go Back
SUBSCRIBE

Contact Us | Editorial Board

© 2009-2018 DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512